Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

Journal of Infectious Diseases

Volumn 178, Issue 4, 1998, Pages 1139-1144

  Stoute, J A ^a   Kester, K E ^b   Krzych, U ^b   Wellde, B T ^b   Hall, T ^b   White, K ^b   Glenn, G ^b   Ockenhouse, C F ^b   Garcon, N ^b   Schwenk, R ^b   Lanar, D E ^b   Sun, P ^b   Momin, P ^b   Wirtz, R A ^b   Golenda, C ^b   Slaoui, M ^b   Wortmann, G ^b   Holland, C ^b   Dowler, M ^b   Cohen, J ^b   Ballou, W R ^b   more..

^a Unit 64109   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; RTS S MALARIA VACCINE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALARIA; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 17344368403     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515657     Document Type: Article

References (5)

1. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997:336:86-91.
2. Sinigaglia F, Guttinger M, Kilgus J, et at. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988;336:778-80.
3. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996;13:1-55.
4. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995;171:1576-85.
5. Hollinger FB, Troisi CL, Pepe PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis 1986;153:156-9.